secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0001171843-24-005923
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika Q3 rev $38.8M (-7% YoY), net loss $29.9M; restructures, sells Arthrosurface, plans Parcus divestiture
--------------------------------------------------------------------------------

- Revenue $38.8M (-7% YoY), net loss $29.9M ($2.03/sh); adj net loss $3.8M ($0.25/sh).
- Integrity Implant System grew 40%+ sequentially, >500 surgeries since launch, Regenerative Solutions up 17%.
- Exiting Arthrosurface (sold) and Parcus Medical (divestiture planned) to focus on HA technology and Commercial Channel.
- Updated 2024 guidance: Commercial Channel +14% to +19%, OEM -8% to -10%, Adj EBITDA $16-18M; restructuring charges $3-5M cash, $27-29M non-cash.
- First Hyalofast PMA module filed Oct 28; Cingal NDA path progress including acquisition of Aristospan NDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184324005923/0001171843-24-005923-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184324005923/f8k_103124.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-005923

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer